Hualan Biological Vaccine Inc.

SZSE:301207 Stock Report

Market Cap: CN¥11.0b

Hualan Biological Vaccine Past Earnings Performance

Past criteria checks 1/6

Hualan Biological Vaccine's earnings have been declining at an average annual rate of -3.6%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been declining at an average rate of 0.06% per year. Hualan Biological Vaccine's return on equity is 8.2%, and it has net margins of 30.2%.

Key information

-3.6%

Earnings growth rate

-6.9%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate-0.06%
Return on equity8.2%
Net Margin30.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly

Oct 08
Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly

Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk

Jul 25
Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk

Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's

Jun 11
Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's

Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)

Apr 03
Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)

Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next

Apr 02
Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next

Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity

Apr 01
Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity

An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued

Mar 04
An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued

Revenue & Expenses Breakdown

How Hualan Biological Vaccine makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:301207 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,650498719100
30 Jun 242,2967771,02187
31 Mar 242,30080599981
31 Dec 232,4108601,04091
30 Sep 231,98464585996
30 Jun 23915330285103
31 Mar 231,956614856128
01 Jan 231,826520805135
30 Sep 221,997598856146
30 Jun 222,8799481,207148
31 Mar 221,833624640148
01 Jan 221,830621649144
30 Sep 212,6081,0041,015146
30 Jun 212,441922960155
31 Mar 212,439934960125
31 Dec 202,426925959111
31 Dec 191,04937534673
31 Dec 1880327038153
31 Dec 17285-7721664

Quality Earnings: 301207 has high quality earnings.

Growing Profit Margin: 301207's current net profit margins (30.2%) are lower than last year (32.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 301207's earnings have declined by 3.6% per year over the past 5 years.

Accelerating Growth: 301207's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301207 had negative earnings growth (-22.8%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).

Return on Equity

High ROE: 301207's Return on Equity (8.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 10:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hualan Biological Vaccine Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yizheng YangChina International Capital Corporation Limited
Kai WangCitic Securities Co., Ltd.
Mingrui WangEverbright Securities Co. Ltd.